Congxin Liang

Title: Congxin Liang: Innovator in Pharmaceutical Synthesis

Introduction

Congxin Liang is a notable inventor based in Jupiter, FL (US). He has made significant contributions to the field of pharmaceutical synthesis, particularly in the development of selective kinase inhibitors. His work is characterized by innovative methods that enhance the efficiency and effectiveness of drug production.

Latest Patents

Congxin Liang holds a patent for a method of synthesizing a furoimidazopyridine compound. The patent, titled "Method for synthesizing furoimidazopyridine compound, polymorphic substance and polymorphic substance of salt," describes a process for creating the compound 2-[(2R,5S)-5-[2-methylfuro[3,2-b]imidazo[4,5-d]pyridin-1-yl]tetrahydropyran-2-yl]acetonitrile. This compound serves as a selective JAK1/TYK2 kinase inhibitor. The synthesis method utilizes 7-chloro-6-nitrofuro[3,2-b]pyridine as the starting material and involves nucleophilic substitution, palladium on carbon reduction, and cyclization reactions. The method is noted for its mild reaction conditions, high product yield, and high purity, making it suitable for industrial production. Additionally, the patent covers the crystal form of the compound and its salts, which exhibit favorable physical and chemical properties for drug development.

Career Highlights

Congxin Liang is currently employed at Biohaven Therapeutics Ltd., where he continues to advance his research in pharmaceutical innovations. His work has positioned him as a key figure in the development of new therapeutic agents.

Collaborations

He has collaborated with notable colleagues, including Laibao Wang and Haihui Liu, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Congxin Liang's contributions to the field of pharmaceutical synthesis exemplify the impact of innovative methods in drug development. His patent for synthesizing a selective kinase inhibitor highlights his commitment to advancing medical science.